Accelerate Diagnostics Inc. [NASDAQ: AXDX] jumped around 1.19 points on Tuesday, while shares priced at $11.29 at the close of the session, up 11.78%. Accelerate Diagnostics Inc. stock is now -33.20% down from its year-to-date (YTD) trading value. AXDX Stock saw the intraday high of $11.45 and lowest of $10.2401 per share. The company’s 52-week high price is 24.00, which means current price is +149.23% above from all time high which was touched on 01/16/20.
Compared to the average trading volume of 499.86K shares, AXDX reached a trading volume of 1066390 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Accelerate Diagnostics Inc. [AXDX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AXDX shares is $13.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AXDX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Accelerate Diagnostics Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on September 27, 2019. The new note on the price target was released on November 07, 2018, representing the official price target for Accelerate Diagnostics Inc. stock. Previously, the target price had yet another raise to $25, while Craig Hallum analysts kept a Hold rating on AXDX stock.
The Average True Range (ATR) for Accelerate Diagnostics Inc. is set at 0.75, with the Price to Sales ratio for AXDX stock in the period of the last 12 months amounting to 61.75.
How has AXDX stock performed recently?
Accelerate Diagnostics Inc. [AXDX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.85. With this latest performance, AXDX shares gained by 28.08% in over the last four-week period, additionally sinking by -31.33% over the last 6 months – not to mention a drop of -43.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AXDX stock in for the last two-week period is set at 70.01, with the RSI for the last a single of trading hit 76.66, and the three-weeks RSI is set at 62.34 for Accelerate Diagnostics Inc. [AXDX]. The present Moving Average for the last 50 days of trading for this stock 9.39, while it was recorded at 9.94 for the last single week of trading, and 14.20 for the last 200 days.
Accelerate Diagnostics Inc. [AXDX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Accelerate Diagnostics Inc. [AXDX] shares currently have an operating margin of -783.38 and a Gross Margin at +47.33. Accelerate Diagnostics Inc.’s Net Margin is presently recorded at -906.80.
Return on Total Capital for AXDX is now -47.89, given the latest momentum, and Return on Invested Capital for the company is -55.52. Return on Equity for this stock declined to -337.25, with Return on Assets sitting at -52.74. Additionally, AXDX Total Debt to Total Capital is recorded at 105.82, with Total Debt to Total Assets ending up at 99.74.
Reflecting on the efficiency of the workforce at the company, Accelerate Diagnostics Inc. [AXDX] managed to generate an average of -$306,564 per employee. Receivables Turnover for the company is 3.66 with a Total Asset Turnover recorded at a value of 0.06.Accelerate Diagnostics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.70 and a Current Ratio set at 16.00.
Earnings analysis for Accelerate Diagnostics Inc. [AXDX]
With the latest financial reports released by the company, Accelerate Diagnostics Inc. posted -0.38/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AXDX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Accelerate Diagnostics Inc. go to 30.00%.
Insider trade positions for Accelerate Diagnostics Inc. [AXDX]
There are presently around $299 million, or 55.30% of AXDX stock, in the hands of institutional investors. The top three institutional holders of AXDX stocks are: ORACLE INVESTMENT MANAGEMENT INC with ownership of 4,102,287, which is approximately -2.631% of the company’s market cap and around 3.80% of the total institutional ownership; CREDIT SUISSE AG/, holding 2,987,870 shares of the stock with an approximate value of $30.18 million in AXDX stocks shares; and BIRCHVIEW CAPITAL, LP, currently with $22.16 million in AXDX stock with ownership of nearly 0.458% of the company’s market capitalization.
Positions in Accelerate Diagnostics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 46 institutional holders increased their position in Accelerate Diagnostics Inc. [NASDAQ:AXDX] by around 1,415,454 shares. Additionally, 38 investors decreased positions by around 2,111,302 shares, while 35 investors held positions by with 26,106,338 shares. The mentioned changes placed institutional holdings at 29,633,094 shares, according to the latest SEC report filing. AXDX stock had 14 new institutional investments in for a total of 252,610 shares, while 10 institutional investors sold positions of 115,855 shares during the same period.